The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
ACE2 of the heart: From angiotensin I to angiotensin (1–7)
Abstract
Angiotensin II (Ang II), a bioactive peptide of the renin-angiotensin system (RAAS), plays an important role in the development of cardiovascular diseases (CVD). Pharmacological inhibition of angiotensin-converting enzyme (ACE), the Ang II forming enzyme, or specific blockade of Ang II binding to angiotensin type 1 receptor (AT1R) through which it exerts its deleterious effects, were shown to provide some protection against progression of CVD. The ACE-Ang II-AT1R axis has been challenged over the last few years with RAAS components able to counterbalance the effects of the main axis. The ACE homologue ACE2 efficiently hydrolyses Ang II to form Ang (1-7), a peptide that exerts actions opposite to those of Ang II. In contrast to the Ang II axis, the role of the ACE2-Ang (1-7) axis in cardiac function is largely obscure. Ang (1-7) is present in the viable myocardium, and its formation depends on Ang II as a substrate. The expression of this peptide is associated with cardiac remodeling: it is lost in the infarcted area and significantly increased in the border area. Low doses of Ang (1-7) improve cardiac output and antagonize Ang II-induced vasoconstriction. The type of Ang (1-7) biological activity is tissue specific and dose dependent. These findings point to a possible protective role for Ang (1-7) in abating the Ang II-induced actions. The elevated expression of Ang (1-7) in failing heart tissue paralleled the expression of its forming enzyme, ACE2. Several observations and experimental evidence suggest a beneficial role for ACE2 in cardiovascular function. Elevated ACE2 expression at the initial stage of several pathologies which decline with progression of disease might indicate a protective role for ACE2. Genetic manipulation of ACE2 expression, either targeted disruption or overexpression, point to the possible significance of this enzyme in cardiac function. Based on the above, a therapeutic approach that will amplify the ACE2-Ang (1-7) axis could provide further protection against the development of CVD. It turns out that the merits of currently used drugs--ACE inhibitors, AT1R blockers and mineralocorticoid receptor blockers (MRB) - lay beyond their direct effects on suppression of the ACE-Ang II-AT1R axis as they also increase cardiac ACE2 and Ang (1-7) significantly.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., Donovan, M., Woolf, B., Robison, K., Jeyaseelan, R., et al. (2000) · Circulation Research · doi:10.1161/01.res.87.5.e1 · Cited by 2,485
A Human Homolog of Angiotensin-converting Enzyme
Tipnis, S. R., Hooper, N. M., Hyde, R., Karran, E., Christie, G., & Turner, A. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002615200 · Cited by 2,009
Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas
Santos, R. A. S., e Silva, A. C. S., Maric, C., Silva, D. M. R., Machado, R. P., de Buhr, I., Heringer-Walther, S., Pinheiro, S. V. B., Lopes, M. T., Bader, M., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1432869100 · Cited by 1,801
Angiotensin-converting enzyme 2 is an essential regulator of heart function
Crackower, M. A., Sarao, R., Oudit, G. Y., Yagil, C., Kozieradzki, I., Scanga, S. E., Oliveira-dos-Santos, A. J., da Costa, J., Zhang, L., Pei, Y., et al. (2002) · Nature · doi:10.1038/nature00786 · Cited by 1,733 · cited 1×
“Mice with targeted disruption of ACE2 develop abnormal heart function which progressed with age and was more pronounced in males [55].”
BackgroundFerrario, C. M., Jessup, J., Chappell, M. C., Averill, D. B., Brosnihan, K. B., Tallant, E. A., Diz, D. I., & Gallagher, P. E. (2005) · Circulation · doi:10.1161/circulationaha.104.510461 · Cited by 1,565
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
Vickers, C., Hales, P., Kaushik, V., Dick, L., Gavin, J., Tang, J., Godbout, K., Parsons, T., Baronas, E., Hsieh, F., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200581200 · Cited by 1,407
Urata, H., Kinoshita, A., Misono, K. S., Bumpus, F. M., & Husain, A. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45712-2 · Cited by 880
RICE, G. I., THOMAS, D. A., GRANT, P. J., TURNER, A. J., & HOOPER, N. M. (2004) · Biochemical Journal · doi:10.1042/bj20040634 · Cited by 619
Ishiyama, Y., Gallagher, P. E., Averill, D. B., Tallant, E. A., Brosnihan, K. B., & Ferrario, C. M. (2004) · Hypertension · doi:10.1161/01.hyp.0000124667.34652.1a · Cited by 564
Recent Progress in Angiotensin II Type 2 Receptor Research in the Cardiovascular System
Horiuchi, M., Akishita, M., & Dzau, V. J. (1999) · Hypertension · doi:10.1161/01.hyp.33.2.613 · Cited by 473
Myocardial infarction increases ACE2 expression in rat and humans
Burrell, L. M., Risvanis, J., Kubota, E., Dean, R. G., MacDonald, P. S., Lu, S., Tikellis, C., Grant, S. L., Lew, R. A., Smith, A. I., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi114 · Cited by 423
G-Protein–Coupled Receptor Mas Is a Physiological Antagonist of the Angiotensin II Type 1 Receptor
Kostenis, E., Milligan, G., Christopoulos, A., Sanchez-Ferrer, C. F., Heringer-Walther, S., Sexton, P. M., Gembardt, F., Kellett, E., Martini, L., Vanderheyden, P., et al. (2005) · Circulation · doi:10.1161/01.cir.0000160867.23556.7d · Cited by 415
Angiotensin-(1-7) Dilates Canine Coronary Arteries Through Kinins and Nitric Oxide
Brosnihan, K. B., Li, P., & Ferrario, C. M. (1996) · Hypertension · doi:10.1161/01.hyp.27.3.523 · Cited by 404
Angiotensin and cell growth: a link to cardiovascular hypertrophy?
Schelling, P., Fischer, H., & Ganten, D. (1991) · Journal of Hypertension · doi:10.1097/00004872-199101000-00002 · Cited by 388
Yamamoto, K., Ohishi, M., Katsuya, T., Ito, N., Ikushima, M., Kaibe, M., Tatara, Y., Shiota, A., Sugano, S., Takeda, S., et al. (2006) · Hypertension · doi:10.1161/01.hyp.0000205833.89478.5b · Cited by 323
Angiotensin-(1–7) Attenuates the Development of Heart Failure After Myocardial Infarction in Rats
Loot, A. E., Roks, A. J. M., Henning, R. H., Tio, R. A., Suurmeijer, A. J. H., Boomsma, F., & van Gilst, W. H. (2002) · Circulation · doi:10.1161/01.cir.0000013847.07035.b9 · Cited by 321
Zisman, L. S., Keller, R. S., Weaver, B., Lin, Q., Speth, R., Bristow, M. R., & Canver, C. C. (2003) · Circulation · doi:10.1161/01.cir.0000094734.67990.99 · Cited by 308
Gottlieb, S. S., Dickstein, K., Fleck, E., Kostis, J., Levine, T. B., LeJemtel, T., & DeKock, M. (1993) · Circulation · doi:10.1161/01.cir.88.4.1602 · Cited by 291
Ocaranza, M. P., Godoy, I., Jalil, J. E., Varas, M., Collantes, P., Pinto, M., Roman, M., Ramirez, C., Copaja, M., Diaz-Araya, G., et al. (2006) · Hypertension · doi:10.1161/01.hyp.0000237862.94083.45 · Cited by 273
Masaki, H., Kurihara, T., Yamaki, A., Inomata, N., Nozawa, Y., Mori, Y., Murasawa, S., Kizima, K., Maruyama, K., Horiuchi, M., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1885 · Cited by 260
The Role of ACE2 in Cardiovascular Physiology
Oudit, G. Y., Crackower, M. A., Backx, P. H., & Penninger, J. M. (2003) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(02)00233-5 · Cited by 254
Pörsti, I., Bara, A. T., Busse, R., & Hecker, M. (1994) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1994.tb14787.x · Cited by 239
Huentelman, M. J., Grobe, J. L., Vazquez, J., Stewart, J. M., Mecca, A. P., Katovich, M. J., Ferrario, C. M., & Raizada, M. K. (2005) · Experimental Physiology · doi:10.1113/expphysiol.2005.031096 · Cited by 237
Impairment of In Vitro and In Vivo Heart Function in Angiotensin-(1-7) Receptor Mas Knockout Mice
Santos, R. A. S., Castro, C. H., Gava, E., Pinheiro, S. V. B., Almeida, A. P., de Paula, R. D., Cruz, J. S., Ramos, A. S., Rosa, K. T., Irigoyen, M. C., et al. (2006) · Hypertension · doi:10.1161/01.hyp.0000215289.51180.5c · Cited by 237
Redox‐dependent signalling by angiotensin II and vascular remodelling in hypertension
Touyz, R. M., Tabet, F., & Schiffrin, E. L. (2003) · Clinical and Experimental Pharmacology and Physiology · doi:10.1046/j.1440-1681.2003.03930.x · Cited by 236
Iyer, S. N., Ferrario, C. M., & Chappell, M. C. (1998) · Hypertension · doi:10.1161/01.hyp.31.1.356 · Cited by 228
Ye, M., Wysocki, J., Naaz, P., Salabat, M. R., LaPointe, M. S., & Batlle, D. (2004) · Hypertension · doi:10.1161/01.hyp.0000126192.27644.76 · Cited by 221
Novel Peptide Inhibitors of Angiotensin-converting Enzyme 2
Huang, L., Sexton, D. J., Skogerson, K., Devlin, M., Smith, R., Sanyal, I., Parry, T., Kent, R., Enright, J., Wu, Q.-L., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212934200 · Cited by 215
Donoghue, M. (2003) · Journal of Molecular and Cellular Cardiology · doi:10.1016/s0022-2828(03)00177-9 · Cited by 214
Igase, M., Strawn, W. B., Gallagher, P. E., Geary, R. L., & Ferrario, C. M. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00068.2005 · Cited by 203
Serneri, G. G. N., Boddi, M., Cecioni, I., Vanni, S., Coppo, M., Papa, M. L., Bandinelli, B., Bertolozzi, I., Polidori, G., Toscano, T., et al. (2001) · Circulation Research · doi:10.1161/hh0901.089882 · Cited by 197
Keidar, S., Gamliel-Lazarovich, A., Kaplan, M., Pavlotzky, E., Hamoud, S., Hayek, T., Karry, R., & Abassi, Z. (2005) · Circulation Research · doi:10.1161/01.res.0000187500.24964.7a · Cited by 193
Self-citationSystemic and regional hemodynamic effects of angiotensin-(1–7) in rats
Sampaio, W. O., Nascimento, A. A. S., & Santos, R. A. S. (2003) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01145.2002 · Cited by 191
Angiotensin-(1–7) Is a Modulator of the Human Renin-Angiotensin System
Roks, A. J. M., van Geel, P. P., Pinto, Y. M., Buikema, H., Henning, R. H., de Zeeuw, D., & van Gilst, W. H. (1999) · Hypertension · doi:10.1161/01.hyp.34.2.296 · Cited by 190
Yamamoto, K., Chappell, M. C., Brosnihan, K. B., & Ferrario, C. M. (1992) · Hypertension · doi:10.1161/01.hyp.19.6.692 · Cited by 189
Angiotensin-(1-7): a new hormone of the angiotensin system.
Ferrario, C. M., Brosnihan, K. B., Diz, D. I., Jaiswal, N., Khosla, M. C., Milsted, A., & Tallant, E. A. (1991) · Hypertension · doi:10.1161/01.hyp.18.5_suppl.iii126 · Cited by 182
Dales, N. A., Gould, A. E., Brown, J. A., Calderwood, E. F., Guan, B., Minor, C. A., Gavin, J. M., Hales, P., Kaushik, V. K., Stewart, M., et al. (2002) · Journal of the American Chemical Society · doi:10.1021/ja0277226 · Cited by 181
Nonpeptide AVE 0991 Is an Angiotensin-(1–7) Receptor Mas Agonist in the Mouse Kidney
Pinheiro, S. V. B., Simões e Silva, A. C., Sampaio, W. O., de Paula, R. D., Mendes, E. P., Bontempo, E. D., Pesquero, J. B., Walther, T., Alenina, N., Bader, M., et al. (2004) · Hypertension · doi:10.1161/01.hyp.0000141438.64887.42 · Cited by 175
Kittleson, M. M., Minhas, K. M., Irizarry, R. A., Ye, S. Q., Edness, G., Breton, E., Conte, J. V., Tomaselli, G., Garcia, J. G. N., & Hare, J. M. (2005) · Physiological Genomics · doi:10.1152/physiolgenomics.00255.2004 · Cited by 174
de Castro, C. H., Souza dos Santos, R. A., Ferreira, A. J., Bader, M., Alenina, N., & Pinto de Almeida, A. (2005) · Hypertension · doi:10.1161/01.hyp.0000175813.04375.8a · Cited by 168
Angiotensin-(1-7) Potentiates the Hypotensive Effect of Bradykinin in Conscious Rats
Paula, R. D., Lima, C. V., Khosla, M. C., & Santos, R. A. S. (1995) · Hypertension · doi:10.1161/01.hyp.26.6.1154 · Cited by 160
Li, N., Zimpelmann, J., Cheng, K., Wilkins, J. A., & Burns, K. D. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00144.2004 · Cited by 155
Production of angiotensin-(1-7) by human vascular endothelium.
Santos, R. A. S., Brosnihan, K. B., Jacobsen, D. W., DiCorleto, P. E., & Ferrario, C. M. (1992) · Hypertension · doi:10.1161/01.hyp.19.2_suppl.ii56 · Cited by 151
Differential responses to angiotensin-(1–7) in the feline mesenteric and hindquarters vascular beds
Osei, S. Y., Ahima, R. S., Minkes, R. K., Weaver, J. P., Khosla, M. C., & Kadowitz, P. J. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90703-k · Cited by 147
Shaltout, H. A., Westwood, B. M., Averill, D. B., Ferrario, C. M., Figueroa, J. P., Diz, D. I., Rose, J. C., & Chappell, M. C. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00139.2006 · Cited by 147
The role of angiotensin II in regulating vascular structural and functional changes in hypertension
Touyz, R. M. (2003) · Current Hypertension Reports · doi:10.1007/s11906-003-0073-2 · Cited by 145
Cardiac Angiotensin-(1-7) in Ischemic Cardiomyopathy
Averill, D. B., Ishiyama, Y., Chappell, M. C., & Ferrario, C. M. (2003) · Circulation · doi:10.1161/01.cir.0000092888.63239.54 · Cited by 132
How to Explain the Differences Between Renin Angiotensin System Modulators
Levy, B. I. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2005.05.005 · Cited by 119
Angiotensin-(1-7) Formation in the Intact Human Heart
Zisman, L. S., Meixell, G. E., Bristow, M. R., et al. (2003) · Circulation · doi:10.1161/01.cir.0000094733.61689.d4 · Cited by 114
Lieb, W., Graf, J., Götz, A., König, I. R., Mayer, B., Fischer, M., Stritzke, J., Hengstenberg, C., Holmer, S. R., Döring, A., et al. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0718-5 · Cited by 111
Angiotensin (1???7) is an antagonist at the type 1 angiotensin II receptor
Mahon, J. M., Carr, R. D., Nicol, A. K., & Henderson, I. W. (1994) · Journal of Hypertension · doi:10.1097/00004872-199412000-00010 · Cited by 106
Lijnen, P. J., Petrov, V. V., & Fagard, R. H. (2001) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2001.012 · Cited by 105
Ueda, S., Masumori‐Maemoto, S., 芦野, 和., Nagahara, T., Gotoh, E., Umemura, S., & Ishii, M. (2000) · Hypertension · doi:10.1161/01.hyp.35.4.998 · Cited by 95
Angiotensin-(1-7) and the Rat Aorta: Modulation by the Endothelium
le Tran, Y., & Förster, C. (1997) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199711000-00019 · Cited by 93
Developmental expression of ACE2 in the SHR kidney: A role in hypertension?
Tikellis, C., Cooper, M. E., Bialkowski, K., Johnston, C. I., Burns, W. C., Lew, R. A., Smith, A. I., & Thomas, M. C. (2006) · Kidney International · doi:10.1038/sj.ki.5000428 · Cited by 91
Kacimi, R., & Gerdes, A. M. (2003) · Hypertension · doi:10.1161/01.hyp.0000062465.60601.cc · Cited by 85
Danilczyk, U. G., Eriksson, U., Crackower, M. A., & Penninger, J. M. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0419-x · Cited by 77
Angiotensin(1–7) potentiates bradykinin-induced vasodilatation in man
Ueda, S., Masumori‐Maemoto, S., Wada, A., Ishii, M., Brosnihan, K. B., & Umemura, S. (2001) · Journal of Hypertension · doi:10.1097/00004872-200111000-00010 · Cited by 73
Angiotensin, fibrinolysis, and vascular homeostasis
Vaughan, D. E. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01509-0 · Cited by 72
Davie, A. P., & McMurray, J. J. V. (1999) · Hypertension · doi:10.1161/01.hyp.34.3.457 · Cited by 66
Serine proteases and cardiac function
Wu, Q., Kuo, H.-C., & Deng, G. G. (2004) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2004.09.005 · Cited by 64
The renin-angiotensin system during acute myocardial ischemia in dogs.
Santos, R. A. S., Brum, J. M., Brosnihan, K. B., & Ferrario, C. M. (1990) · Hypertension · doi:10.1161/01.hyp.15.2_suppl.i121 · Cited by 62
A Place in Our Hearts for the Lowly Angiotensin 1-7 Peptide?
Reudelhuber, T. L. (2006) · Hypertension · doi:10.1161/01.hyp.0000209020.69734.73 · Cited by 44
Interaction of ACE2 and integrin β1 in failing human heart
Lin, Q., Keller, R. S., Weaver, B. A., & Zisman, L. S. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.05.005 · Cited by 39
Cited by
Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19
Ni, W., Yang, X., Yang, D., Bao, J., Li, R., Xiao, Y., Hou, C., Wang, H., Liu, J., Yang, D., et al. (2020) · Critical Care · doi:10.1186/s13054-020-03120-0 · Cited by 1,175
Structure analysis of the receptor binding of 2019-nCoV
Chen, Y., Guo, Y., Pan, Y., & Zhao, Z. J. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.02.071 · Cited by 806
Myofibroblast-mediated mechanisms of pathological remodelling of the heart
Weber, K. T., Sun, Y., Bhattacharya, S. K., Ahokas, R. A., & Gerling, I. C. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.158 · Cited by 673
Renin‐angiotensin system revisited
Fyhrquist, F., & Saijonmaa, O. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01981.x · Cited by 642
Receptor Recognition Mechanisms of Coronaviruses: a Decade of Structural Studies
Li, F. (2015) · Journal of Virology · doi:10.1128/jvi.02615-14 · Cited by 573
Metadata
- Authors
- KEIDAR, S., KAPLAN, M., & GAMLIELLAZAROVICH, A.
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-02-01
- Volume
- 73
- Issue
- 3
- Pages
- 463-469
- ISSN
- 0008-6363 (ISSN-L)
- OpenAlex
- W2134074925
- Cited by
- 278
- References
- 64
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.